ADAGENE INC - ADS, EACH REPRESENTING 1.25
ADAGENE INC - ADS, EACH REPRESENTING 1.25
Certificat de dépôt · US0053291078 · ADAG · A2QN45 (XNAS)
Aperçu
1,99 USD
8,15 % 0,15 USD
NASDAQ (XNAS) · Cours et graphiques actuels sur MoneyPeak
06.06.2025 19:59

Cours actuels de ADAGENE INC - ADS, EACH REPRESENTING 1.25

BourseTickerDeviseDernier échangeCoursVariation journalière
XNAS: NASDAQ
NASDAQ
ADAG
USD
06.06.2025 19:59
1,99 USD
1,76 USD
+13,07 %

Performance

Jour Semaine Mois 3 mois 6 mois 1 an 5 ans
0,00 % -4,56 % 24,76 % -3,86 % -3,16 % -33,22 % -93,36 %

Profil de l'entreprise pour ADAGENE INC - ADS, EACH REPRESENTING 1.25 Certificat de dépôt

Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.

Données de l'entreprise

Nom ADAGENE INC - ADS, EACH REPRESENTING 1.25
Société Adagene Inc.
Symbole ADAG
Site web https://www.adagene.com
Marché d'origine XNAS NASDAQ
WKN A2QN45
ISIN US0053291078
Type de titre Certificat de dépôt
Secteur Healthcare
Industrie Biotechnology
PDG Dr. Peter P. Luo Ph.D.
Capitalisation boursière 54 Mio
Pays Chine
Devise USD
Employés 0,1 T
Adresse Building C14, 215123 Suzhou
Date d'introduction en bourse 2021-02-09

Symboles boursiers

Nom Symbole
Frankfurt 978.F
NASDAQ ADAG

Autres actions

Les investisseurs qui détiennent ADAGENE INC - ADS, EACH REPRESENTING 1.25 ont également les actions suivantes dans leur portefeuille :
ENBRIDGE 24/54 FLR
ENBRIDGE 24/54 FLR Obligation
SEMPRA 22/29
SEMPRA 22/29 Obligation
La plateforme financière MoneyPeak suit et analyse les investissements et les portefeuilles. Du dépôt de titres à l'achat de crypto.
Utile, simple et gratuit. Actions, ETF, ETC, ETN, indices, fonds, obligations, certificats, devises, options, droits de souscription.
Mentions légales Protection des données Blog Communauté Retour d'information Changelog
Im App Store herunterladen Bei Google Play herunterladen
Tous droits réservés © LCP GmbH 2025